Coya Therapeutics (NASDAQ:COYA) Releases Earnings Results, Misses Expectations By $0.26 EPS

Coya Therapeutics (NASDAQ:COYA) posted its quarterly earnings data on Monday. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26), FiscalAI reports. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. The firm had revenue of $3.96 million during the quarter, compared to the consensus estimate of $1.93 million.

Coya Therapeutics Stock Down 4.6%

Coya Therapeutics stock opened at $4.53 on Monday. The company has a market capitalization of $94.77 million, a PE ratio of -4.08 and a beta of 0.23. Coya Therapeutics has a 12-month low of $3.94 and a 12-month high of $7.75. The firm’s fifty day moving average is $4.77 and its 200 day moving average is $5.59.

Institutional Investors Weigh In On Coya Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Alyeska Investment Group L.P. bought a new position in shares of Coya Therapeutics during the 4th quarter worth about $4,640,000. AWM Investment Company Inc. bought a new stake in Coya Therapeutics in the 4th quarter valued at about $4,205,000. Private Management Group Inc. bought a new stake in Coya Therapeutics in the 4th quarter valued at about $1,626,000. Marshall Wace LLP raised its stake in Coya Therapeutics by 438.8% during the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after buying an additional 183,533 shares during the period. Finally, Dauntless Investment Group LLC boosted its holdings in Coya Therapeutics by 199.5% in the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after acquiring an additional 101,932 shares in the last quarter. 39.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on COYA. D. Boral Capital restated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, January 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, February 2nd. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Coya Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.